Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease in which ventricular electrical instability may precede marked structural change. Although the right ventricle is classically emphasized, contemporary concepts of arrhythmogenic cardiomyopathy also recognize left-dominant and biventricular phenotypes. Ventricular premature beats, nonsustained ventricular tachycardia, sustained monomorphic VT, polymorphic VT, and sudden cardiac arrest may occur across this spectrum.
Risk stratification therefore requires more than a single imaging measurement or genetic result. The clinically relevant question is whether a patient has a sufficiently high probability of life-threatening ventricular arrhythmia to justify an implantable cardioverter-defibrillator (ICD), closer surveillance, or a change in exercise and medical management.
Assessment should combine the arrhythmic history, ventricular function, tissue characterization, electrocardiographic findings, family history, genotype, and exposure to triggers such as intense endurance exercise. Repeated evaluation is essential because disease expression and arrhythmic risk can evolve over time.
Why Arrhythmic Risk Is Difficult To Estimate
ARVC has variable penetrance and age-dependent expression. A patient may carry a pathogenic desmosomal variant with limited imaging abnormalities, while another may have extensive scar and recurrent VT without an identifiable mutation. Electrical disease can also be disproportionate to ventricular dilation, particularly during earlier stages.
The substrate is often patchy and located in the “triangle of dysplasia,” involving the right ventricular outflow tract, inflow region, and apex. Fibrofatty replacement, myocardial inflammation, and scar create areas of slow conduction that support re-entry. Left ventricular involvement may add diffuse fibrosis, systolic dysfunction, and a different VT morphology, making a right-ventricle-only assessment inadequate.
Risk estimates are also influenced by ascertainment. A person referred after an aborted cardiac arrest has a very different baseline probability from an asymptomatic relative identified through family screening. Interpretation must therefore account for the reason for presentation, duration of follow-up, treatment effects, and the quality of available phenotype data.
Clinical Features That Raise Concern
Previous sustained VT, ventricular fibrillation, or cardiac arrest is the strongest practical marker of future malignant arrhythmia. In these patients, secondary-prevention ICD therapy is generally considered unless the event was clearly caused by a reversible factor unrelated to the cardiomyopathy. The morphology and reproducibility of VT can help define the substrate, but they do not remove the significance of the clinical event.
Unexplained syncope is particularly concerning when it is abrupt, occurs during exertion, or is accompanied by palpitations. Syncope attributed to vasovagal mechanisms or orthostatic hypotension should not be treated as equivalent to arrhythmic syncope, yet uncertainty should prompt careful rhythm monitoring rather than premature reassurance.
Nonsustained VT, frequent premature ventricular contractions, and increasing ectopic burden are important intermediate markers. Exercise-induced ventricular ectopy or VT may signal an active arrhythmogenic substrate. A high PVC count alone does not determine ICD need, but it gains importance when combined with reduced ejection fraction, late gadolinium enhancement, a pathogenic variant, or a concerning family history.
Imaging, Electrocardiography, And Genetics
The 12-lead ECG may show T-wave inversion beyond V1, epsilon-like signals, prolonged terminal activation, ventricular conduction delay, or localized QRS fragmentation. These findings support disease recognition and phenotyping, although a normal ECG does not exclude clinically important arrhythmic risk. Serial ECGs can reveal progression that is missed in a single assessment.
Echocardiography evaluates regional right ventricular akinesia, dyskinesia, aneurysms, fractional area change, global function, and left ventricular performance. Cardiac magnetic resonance adds measurements of right ventricular volumes and ejection fraction, as well as late gadolinium enhancement and edema patterns. Scar burden and left ventricular fibrosis are especially relevant when the phenotype extends beyond the right ventricle.
Genetic testing is valuable for cascade screening and for identifying disease-associated variants, particularly in desmosomal genes such as PKP2, DSP, DSG2, and DSC2. A pathogenic variant can strengthen the diagnosis and family evaluation, but genotype should not be used in isolation to prescribe an ICD. Conversely, a negative panel does not exclude disease because of incomplete variant detection, unrecognized genes, or phenocopies.
Integrating Risk Models With Clinical Judgment
The ARVC risk calculator estimates the probability of sustained ventricular arrhythmia over a defined period using variables such as age, sex, recent cardiac syncope, nonsustained VT, PVC burden, right ventricular ejection fraction, and indexed right ventricular end-diastolic volume. It can provide a transparent starting point for shared decision-making, especially in primary prevention.
Risk models have boundaries. They were developed from selected cohorts, depend on accurate measurements, and may not fully represent left-dominant disease, pediatric patients, advanced heart failure, or emerging genetic subgroups. The model output should therefore be interpreted alongside the patient’s trajectory and not as an automatic ICD prescription threshold.
A practical assessment separates established high-risk findings from modifying factors. Established high-risk findings include prior ventricular fibrillation, sustained VT with hemodynamic compromise, and severe ventricular dysfunction. Modifying features include arrhythmic syncope, recurrent nonsustained VT, extensive scar, a high ectopic burden, male sex in some cohorts, younger age at presentation, and a family history of sudden death. Exercise exposure and recent disease progression also matter.
| Risk domain | Findings that increase concern | How it informs management |
|---|---|---|
| Prior events | Cardiac arrest, ventricular fibrillation, sustained VT | Usually supports secondary-prevention ICD evaluation |
| Symptoms | Unexplained or exertional syncope, sudden palpitations | Requires rhythm investigation and may strengthen primary-prevention decisions |
| Rhythm monitoring | Nonsustained VT, frequent PVCs, increasing burden, exercise-induced VT | Adds weight when combined with structural or genetic disease |
| Ventricular structure | Reduced RV or LV ejection fraction, marked dilation, regional aneurysms | Indicates disease severity and may increase arrhythmic risk |
| Tissue characterization | Extensive late gadolinium enhancement or biventricular scar | Supports a broader arrhythmogenic substrate assessment |
| Genetics and family history | Pathogenic variant, multiple affected relatives, premature sudden death | Guides family screening and contextualizes individual risk |
| Modifiers | Endurance exercise, inflammatory episodes, progressive phenotype | Supports activity restriction, closer follow-up, and reassessment |
Choosing An Implantable Cardioverter-Defibrillator
ICD decisions should balance the anticipated reduction in sudden death against inappropriate shocks, lead complications, infection, psychological effects, and the possibility of inappropriate treatment for supraventricular tachycardia. Shared decision-making is especially important for younger patients who may face decades of device-related interventions.
For secondary prevention, the clinical context is usually decisive. Primary prevention is more nuanced and should consider ventricular function, documented arrhythmias, syncope, scar, genotype, age, comorbidity, and patient preferences. A subcutaneous ICD may be attractive when pacing is not required, whereas a transvenous system may be preferred when antitachycardia pacing or bradycardia support is likely to be useful.
Device programming can reduce avoidable shocks. Longer detection intervals, higher rate cutoffs when appropriate, discriminators for supraventricular tachycardia, and antitachycardia pacing are central considerations. Catheter ablation can reduce recurrent VT and ICD therapies, but it does not substitute for an ICD when the underlying risk of sudden death remains high.
Atrial arrhythmias can coexist with arrhythmogenic cardiomyopathy and complicate device interpretation. Their management should be separated from ventricular sudden-death prevention. When atrial fibrillation creates a need for stroke prevention but anticoagulation is unsuitable, evidence on left atrial appendage occlusion may inform a parallel treatment discussion; this does not address the ventricular arrhythmia indication for an ICD.
Exercise, Follow-Up, And Family Screening
High-intensity endurance exercise is associated with earlier disease expression, greater ventricular dysfunction, and more ventricular arrhythmias in susceptible individuals. Patients with a confirmed or probable diagnosis should receive individualized counseling that considers competitive sport, occupational exertion, recreational training, symptoms, and phenotype severity. Complete inactivity is not universally required, but sustained high-intensity exercise should generally be avoided.
Follow-up should include symptom review, ECG, ambulatory monitoring, echocardiography, and periodic cardiac magnetic resonance when clinically useful. Monitoring intervals should shorten after syncope, a rise in PVC burden, new nonsustained VT, ventricular function decline, inflammatory symptoms, or a change in exercise exposure. ICD interrogation can reveal asymptomatic episodes and help distinguish appropriate from inappropriate therapies.
First-degree relatives require structured evaluation, even when they feel well. Genetic cascade testing is most informative when a clearly pathogenic familial variant has been identified. Relatives who are genotype-positive or phenotype-positive need longitudinal surveillance, while a negative result for the known familial variant may substantially reduce the need for repeated cardiomyopathy testing, subject to specialist interpretation.
A Practical Risk Assessment Workflow
A consistent workflow helps prevent overreliance on any single marker:
- Confirm the phenotype and exclude phenocopies such as myocarditis, sarcoidosis, ischemic scar, and isolated idiopathic RV outflow tract ectopy.
- Document prior arrest, sustained VT, syncope characteristics, PVC burden, nonsustained VT, and exercise-related rhythm changes.
- Quantify right and left ventricular size and function using reproducible imaging methods.
- Review late gadolinium enhancement, family history, genetic findings, medication exposure, and exercise pattern.
- Recalculate risk after meaningful clinical change and record the rationale for ICD, ablation, surveillance, or conservative management.
This process also improves communication between inherited cardiomyopathy clinics, electrophysiologists, imaging specialists, genetic counselors, and primary clinicians. A documented estimate should explain which findings drove the decision, what uncertainties remain, and when reassessment will occur.
Risk stratification in ARVC is a moving clinical judgment rather than a one-time label. Integrating clinical events, rhythm burden, ventricular remodeling, myocardial scar, genetics, and lifestyle exposure offers a more reliable basis for preventing sudden cardiac death while limiting unnecessary device treatment. Clinicians and researchers can deepen this work by applying standardized phenotyping, enrolling diverse patient populations, and sharing longitudinal outcomes through rigorous electrophysiology research and clinical reporting.